Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 1/20 | 0.46 |
| ▸ | TBK1 | Q9UHD2 | 3/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.44 |
| ▸ | KDR | P35968 | 4/20 | 0.44 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.44 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.44 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.42 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.42 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.42 |
| ▸ | ACACB | O00763 | 3/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | F10 | P00742 | 1/20 | 0.40 |
| ▸ | PLG | P00747 | 1/20 | 0.40 |
| ▸ | PLAU | P00749 | 1/20 | 0.40 |
| ▸ | PLAT | P00750 | 1/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.40 |
| ▸ | CHEK2 | O96017 | 3/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14090374 | 0.90 | MGLL (0.41) | FGFR1KDRFGFR2FGFR3TLR9 | |
| SCHEMBL14090235 | 0.88 | HDAC6 (0.42) | FGFR1KDRFGFR2FGFR3PDGFRB | |
| SCHEMBL14090227 | 0.88 | FGFR1 (0.49) | CARM1TBK1FGFR1KDRFGFR2 | |
| SCHEMBL14090419 | 0.85 | RIPK1 (0.46) | CARM1TBK1FGFR1KDRFGFR2 | |
| SCHEMBL1509617 | 0.85 | GSK3B (0.54) | CARM1TBK1FGFR1KDRFGFR3 | |
| SCHEMBL14090211 | 0.85 | PKN1 (0.44) | FGFR1KDRFGFR2FGFR3TLR9 | |
| SCHEMBL14090259 | 0.84 | ACACB (0.46) | FGFR1KDRFGFR2FGFR3ACACB | |
| SCHEMBL14090244 | 0.84 | MGLL (0.50) | FGFR1KDRACACBF2F10 | |
| SCHEMBL14091093 | 0.83 | TBK1 (0.40) | CARM1TBK1FGFR1KDRFGFR2 | |
| SCHEMBL12834014 | 0.83 | MEN1 (0.48) | TBK1TLR7F10ABL1BCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629147-B2 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION (US) | 2014-01-14 | — | — | US | disclosed |
| US-8629147-B2 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION (US) | 2014-01-14 | — | — | US | disclosed |
| US-20080207635-A1 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION | 2008-08-28 | — | — | US | disclosed |
| US-20080207635-A1 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207635-A1 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | LCK, MALT1, MYD88 | CARM1 785/4885TBK1 236/4885FGFR1 632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.